Research programme: anti-CMV monoclonal antibodies - Mitsubishi Tanabe Pharma

Drug Profile

Research programme: anti-CMV monoclonal antibodies - Mitsubishi Tanabe Pharma

Latest Information Update: 26 May 2010

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 26 May 2010 Discontinued - Preclinical for Cytomegalovirus infections in Japan (unspecified route)
  • 01 Oct 2007 Mitsubishi Pharma Corporation merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation
  • 21 Mar 2006 Preclinical trials in Cytomegalovirus infections treatment in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top